This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Resumen de acción CNCE
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Concert Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.37 |
| 52 Week High | US$8.55 |
| 52 Week Low | US$2.66 |
| Beta | 0.52 |
| 1 Month Change | 0% |
| 3 Month Change | 92.86% |
| 1 Year Change | 203.26% |
| 3 Year Change | -9.22% |
| 5 Year Change | -64.31% |
| Change since IPO | -40.97% |
Noticias y actualizaciones recientes
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03Rentabilidad de los accionistas
| CNCE | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -0.1% | 4.4% | 0.6% |
| 1Y | 203.3% | 2.8% | 23.9% |
Rentabilidad vs. Industria: CNCE exceeded the US Biotechs industry which returned 8.9% over the past year.
Rentabilidad vs. Mercado: CNCE exceeded the US Market which returned -5.5% over the past year.
Volatilidad de los precios
| CNCE volatility | |
|---|---|
| CNCE Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: CNCE's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: CNCE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2006 | 64 | Roger Tung | www.concertpharma.com |
Resumen de fundamentos de Concert Pharmaceuticals, Inc.
| Estadísticas fundamentales de CNCE | |
|---|---|
| Capitalización bursátil | US$520.71m |
| Beneficios(TTM) | -US$126.68m |
| Ingresos (TTM) | US$32.04m |
16.3x
Ratio precio-ventas (PS)-4.1x
Ratio precio-beneficio (PE)¿Está CNCE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CNCE | |
|---|---|
| Ingresos | US$32.04m |
| Coste de los ingresos | US$102.70m |
| Beneficio bruto | -US$70.66m |
| Otros gastos | US$56.02m |
| Beneficios | -US$126.68m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.04 |
| Margen bruto | -220.53% |
| Margen de beneficio neto | -395.36% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado CNCE a largo plazo?
Ver rendimiento histórico y comparativa